PF-Atlas › Treatments › Inhaled Treprostinil / Tyvaso
Inhaled Treprostinil / Tyvaso
Prostacyclin analog — vasodilation + anti-fibrotic + anti-proliferative in pulmonary vasculature and parenchyma
Clinically established — FDA-approved or positive Phase III. How PF-Atlas grades evidence.
Development stage
Phase III (FDA filing 2026)
Evidence level
Level 1 (Phase III Positive)
Mechanism class
Prostacyclin analog — vasodilation + anti-fibrotic + anti-proliferative in pulmonary vasculature and parenchyma
Timeline
< 1 year
Risk profile
Low-Medium
Developer
United Therapeutics
Key researchers
S. Nathan
Overview
TETON-1 and TETON-2 Phase III: inhaled treprostinil significantly slowed FVC decline and reduced clinical worsening at 52 weeks in IPF. Already FDA-approved for PAH/PH-ILD. FDA submission for IPF expected summer 2026.
How Inhaled Treprostinil / Tyvaso fits into IPF treatment
Inhaled Treprostinil / Tyvaso is classified as Level 1 (Phase III Positive) at the Phase III (FDA filing 2026) stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Inhaled Treprostinil / Tyvaso for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.